FOLH1 and neoplasm: These findings are also comparable to Gafita et al. who reported a superior prognostic accuracy for OS when combining PSA and PSMA-PET tumor volumetry 12 weeks after the start of therapy compared to PSA alone, making them a possible composite efficacy endpoint for clinical trials of mCRPC [6].